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Investment Summary & Thesis
I am buying Walgreens Boots Alliance (WBA) at a price of $56.55. This recommendation is based on its recent transaction
with Village MD, increasing number of COVID-19 vaccines and tests being administered, and the Transformational Cost
Management Program. Today the price sits at $52.03. They have a high dividend yield at 3.87%. Their market cap is
44.96 Billion.

Key Drivers:
•

•

•

VillageMD
o WBA entered into an agreement with VillageMD to invest $1.0 billion in equity and convertible debt over
the next three years, including a $250 million equity investment completed on July 8, 2020. WBA and
VillageMD plan to open 500 to 700 “Village Medical at Walgreens” physician-led primary care clinics in
more than 30 U.S. markets in the next five years. The Company will continue to account for its equity
investment in VillageMD using the equity method of accounting. It is anticipated, assuming full conversion
of the debt, that the Company will hold an approximately 30% ownership interest in VillageMD at the
completion of the investment. The deal would make Walgreens the first national pharmacy chain to
operate full-service medical offices on a large scale. This is going to be huge because the prescriptions
that patients are prescribed are going to be sent right next door to Walgreens, which in turn should
increase revenue in that sector.
Increasing number of COVID- 19 vaccines and tests being administered.
o With COVID-19 vaccines being rolled out, more and more people are getting vaccinated. State
requirements differ but one can sign up on the Walgreen’s app and then go to a nearby Walgreens to get
the vaccine. This will bring in more foot traffic and will be beneficial for the retail pharmacy USA and
international segments. Walgreens wants people to be safe and healthy and administering the vaccine is
a way of doing that.
Transformational Cost Management Program
o The Transformational Cost Management Program is being put into place to help reduce costs. When
looking at the financial data they are incurring more debt to drive long-term growth. This includes buying
more stores and inventory to be turned over into sales. They plan on not opening as many stores as they
planned to save money. They are also planning on saving $2.0 billion by fiscal 2022 instead of the
previous target, which was $1.8 billion. They are also reducing the workforce in the Boots UK portion to
reduce costs as well. This is going to drive up their financials and drive up their stock price.

Key Financials
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Business Description
Company Overview:
Walgreens Boots Alliance, Inc., a Delaware corporation (“Walgreens Boots Alliance”), is a global leader in retail and
wholesale pharmacy, touching millions of lives every day through dispensing and distributing medicines, and through its
convenient retail locations, digital platforms and health and beauty products with sales of $139.5 billion in the fiscal year
ended August 31, 2020. Walgreens Boots Alliance is the largest retail pharmacy, health and daily living destination across
the United States and Europe. Walgreens Boots Alliance and the companies in which it has equity method investments
together have a presence in more than 251 countries and employ more than 450,0001 people. The Company is a global
leader in retail and wholesale pharmacy and, together with the companies in which it has equity method investments, has
over 21,0001 stores in 111 countries. It also has the largest global pharmaceutical wholesale and distribution networks,
with over 4251 distribution centers delivering to more than 250,0002 pharmacies, doctors, health centers and hospitals
each year in more than 201 countries. In addition, Walgreens Boots Alliance is one of the world’s largest purchasers of
prescription drugs and many other health and well- being products. The Company’s size, scale and expertise will help
expand the supply of, and address the rising cost of, prescription drugs in the United States and worldwide. Walgreens
Boots Alliance was incorporated in Delaware in 2014 and is the successor of Walgreen Co., an Illinois corporation, which
was formed in 1909 as a successor to a business founded in 1901. The principal executive offices are located at 108
Wilmot Road, Deerfield, Illinois 60015. The common stock trades on the Nasdaq Stock Market under the symbol “WBA”.
Transactions:
In March 2013, Walgreens, Alliance Boots GmbH (“Alliance Boots”) and AmerisourceBergen Corporation
(“AmerisourceBergen”) announced various agreements and arrangements, including a ten-year pharmaceutical
distribution agreement between Walgreens and AmerisourceBergen pursuant to which the Company sources branded
and generic pharmaceutical products from AmerisourceBergen in the United States and an agreement which provides
AmerisourceBergen the ability to access generic pharmaceutical products through the Company’s global sourcing
enterprise, Walgreens Boots Alliance Development GmbH. In May 2016, certain of these agreements were extended for
three years and are now expected to expire in 2026. As of August 31, 2020, the Company owned 56,854,867
AmerisourceBergen common shares representing approximately 28% of the outstanding AmerisourceBergen common
stock and has designated one member of AmerisourceBergen’s board of directors. As of August 31, 2020, the Company
can acquire up to an additional 8,398,752 AmerisourceBergen shares in the open market and thereafter designate
another member of AmerisourceBergen’s board of directors, subject in each case to applicable legal and contractual
requirements.
On September 19, 2017, the Company announced that it had secured regulatory clearance for an amended and restated
asset purchase agreement to purchase 1,932 stores, three distribution centers and related inventory from Rite Aid
Corporation (“Rite Aid”) for $4.375 billion in cash and other consideration. Consideration included cash of $4,157 million
and the fair value of the option granted to Rite Aid to become a member of the Company’s group purchasing organization,
Walgreens Boots Alliance Development GmbH. During fiscal 2019, this option was terminated resulting in recognition of a
gain in other income (expense). The purchases of these stores occurred in waves during fiscal 2018 and have been
accounted for as business combinations. The transition of the first distribution center and related inventory occurred in
fiscal 2019 and the transition of the remaining two distribution centers and related inventory were completed in fiscal
2020.
On December 12, 2019, the Company entered into an agreement with McKesson Corporation to combine their respective
pharmaceutical wholesale businesses in Germany. The Company will have a 70% controlling equity interest in the joint
venture and McKesson will have a 30% ownership interest. The new joint venture is expected to drive greater economies
of scale in the German pharmaceutical wholesale market. The transaction is expected to close in early fiscal 2021.
On July 8, 2020, the Company entered into an agreement with VillageMD to invest $1.0 billion in equity and convertible
debt over the next three years, including a $250 million equity investment completed on July 8, 2020, subject to the terms
of the agreement. The Company and VillageMD plan to open 500 to 700 “Village Medical at Walgreens” physician-led
primary care clinics in more than 30 U.S. markets in the next five years. The Company will continue to account for its
equity investment in VillageMD using the equity method of accounting. It is anticipated, assuming full conversion of the
debt, that the Company will hold an approximately 30% ownership interest in VillageMD at the completion of the
investment. The deal would make Walgreens the first national pharmacy chain to operate full-service medical offices on a
large scale.
Three Segments

WALGREENS BOOTS ALLIANCE | REPORT BY IRIS BOPARAI

Page | 2

Retail Pharmacy USA
This division operates 9,021 drugstores in 50 states, the District of Columbia, Puerto Rico and the U.S.
Virgin Islands. About 78 percent of the U.S. population lives within five miles of a Walgreens or Duane
Reade pharmacy. It sells prescription and non-prescription drugs, as well as general merchandise,
including household items, convenience and fresh foods, personal care, beauty care, photofinishing and
candy. They filled approximately 818 million prescriptions in fiscal 2020, including immunizations, with
pharmacy accounting for 75 percent of sales. Our expanded omnichannel capabilities provide customers
with convenient access to consumer goods and services, as well as pharmacy and health and wellness
services in communities across America. Integrated with our e-commerce platform, the Walgreens mobile
application allows customers to refill prescriptions through scan technology, receive notifications alerting
when a refill is due and choose in-store pick up, drive-thru or delivery to their home. Customers can also
use the app to order retail products and choose in-store, curbside or drive-thru pick-up. The Walgreens
Find Care platform also includes telehealth service providers, connecting patients and customers with
options to access convenient and affordable care from their mobile devices. They have taken further
steps to develop neighborhood health destinations, working with their strategic partners such as
VillageMD to provide an integrated primary care and pharmacy model that aims to drive better health
outcomes, reduce costs and provide a differentiated patient experience to the communities they serve.
Walgreens also provides specialty pharmacy and mail services and offers in-store clinics and other
healthcare services throughout the United States, and most of which are operated by their healthcare
strategic partners. They have more than 85,000 healthcare service providers, including pharmacists,
pharmacy technicians, nurse practitioners and other health-related professionals. Through them, they
expect to continue to play a growing role in government and employer efforts to control escalating
healthcare costs.
Retail Pharmacy International
This segment operates 4,428 retail stores, with a growing omnichannel and online presence. In Europe,
they are the market leader. The principal retail brands are Boots in the UK, Thailand, Norway, the
Republic of Ireland, the Netherlands and Lithuania, Benavides in Mexico and Ahumada in Chile. The
Boots omnichannel offering is differentiated from that of competitors due to the product brands they own,
such as No7, Boots Pharmaceuticals, Soap & Glory, Liz Earle, Sleek MakeUP, Botanics and the "only at
Boots" exclusive products, together with our long-established reputation for trust and customer care.
Their brands portfolio is enhanced by the in-house product research and development capabilities. Also,
Boots UK is one of the leaders in the optical market, with 550 practices, of which 165 operate on a
franchise basis. Around 30 percent of practices are located in Boots stores with the balance being
standalone optical practices.

Pharmaceutical Wholesale
Their pharmaceutical wholesale division, which mainly operates under the Alliance Healthcare brand,
supplies medicines, other healthcare products and related services to more than 115,000 pharmacies,
doctors, health centers and hospitals each year from 306 distribution centers in 11 countries.
Their wholesale businesses seek to provide high core service levels to pharmacists in terms of frequency
of delivery, product availability, delivery accuracy, timeliness and reliability at competitive prices. This
includes membership of Alphega Pharmacy, our pan-European network for independent pharmacies. In
addition to the wholesale of medicines and other healthcare products, their businesses provide services
to pharmaceutical manufacturers who are increasingly seeking to gain greater control over their product
distribution, while at the same time outsourcing non-core activities. These services include pre-wholesale
and contract logistics (mainly under the Alloga brand), direct deliveries to pharmacies, and innovative and
specialized healthcare services, covering clinical homecare, medicine support, dispensing services,
medicine preparation and clinical trial support (mainly under the Alcura brand). Combined with local
engagement, scale is very important in pharmaceutical wholesaling. In addition to being a leading
pharmaceutical wholesaler and distributor in Europe, they rank as one of the top three in market share in
many of the individual countries in which they operate.
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Revenue Across the Three Segments ($ in Billions)
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Chart Analysis
Retail Pharmacy USA brings in the most income because it has been around the longest. Around 75% of that income
comes from the pharmacy side. With competitors like Amazon using Pill Pack, this could disrupt the pharmacy sales. But
Walgreens is extending their omnichannel allowing customers to have prescriptions sent to their house. Since Walgreens
is a trusted brand and a lot of people already get their prescriptions through them, I don’t see Amazon having a huge
disruption on Walgreen’s revenue. Pharmaceutical wholesale is the second highest and retail pharmacy international is
the third. Retail pharmacy international is relatively new and with the increasing number of stores being build, I see this
increasing in the near future.
COVID-19:
COVID-19 affected many businesses throughout 2019 to
today. Walgreen’s saw a decrease in net income and other
ratios. But Walgreens has been adapting to these unusual
circumstances. In 2020, Walgreen’s began testing people for
COVID-19 at no cost. They offer free rapid testing across the
U.S. Since COVID-19 testing began, Walgreens has
administered more than 2.8 million tests. Also, Walgreen’s has
administering the vaccine as well. Walgreens is one of a
dozen U.S. pharmacy chains partnering with the federal
government that will administer Covid-19 vaccines. The
Centers for Disease Control announced the partnership on
Oct. 30. In the United States, 143 million vaccines have been
administered and 51.6 million people are fully vaccinated.
That accounts for only 15.72% of the population. In the graph
below, you can see the increasing number of people getting
vaccinated. When people book appointments to get the
vaccine, they come into the store and this creates foot traffic.
A lot of people end up buying something on their way out and
that also creates revenue for Walgreens. They have also
created a updated Walgreen app to allow people to order
curbside or even pick up retail orders through the drive thru to
minimize in person contact. Walgreen is also working with
federal and state governments, Walgreens is vaccinating
residents and staff at more than 35,000 long-term care
facilities in 49 states. They will continue to give out
vaccinations with the limited supply provided.
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Transactional Cost Management Program:
The Transformational Cost Management program came into effect due to COVID-19 and decreasing net profits. They are
incurring debt to drive long-term growth but also using store optimization by only opening 232 stores in the U.S compared
to the 250 originally planned. And opening 158 of 200 planned of Boots UK stores. Boots UK restructuring plan is
reducing 11% in the workforce (vs. 7% previously) which could include closing down stores. There are advancing
business process outsourcing partnership with Genpact. They have announced strategic partnership with Verizon for
Network as a Service in U.S which will help save money. There will be continued efficiencies through new pharmacy
processing automation and launch of new pharmacy operating model. The company increased its annual cost savings
target from the Transformational Cost Management Program to in excess of $2.0 billion by fiscal 2022, from the previous
target, which was annual cost savings in excess of $1.8 billion by fiscal 2022. This program will help their financials look
better by saving more.

Management and Corporate Governance

James Skinner has served as Executive Chairman since January 2015, having served as non-executive Chairman of the Board
from July 2012 to January 2015. He is not the Non-Executive Director. Mr. Skinner previously served at the McDonald’s
Corporation as Vice Chairman from January 2003 to June 2012. He was the Chief Executive Officer from November 2004 to June
2012 and as a director from 2004 to June 2012 at McDonald’s Corporation.
Stephano Pessina has served as Chief Executive Officer since July 2015 and as Executive Vice Chairman since January 2015.
He served as Acting Chief Executive Officer from January 2015 to July 2015. Previously, he served as Executive Chairman of
Alliance Boots from July 2007 to December 2014. Prior to that, Mr. Pessina served as Executive Deputy Chairman of Alliance
Boots. Prior to the merger of Alliance UniChem and Boots Group, Mr. Pessina was Executive Deputy Chairman of Alliance
UniChem, previously having been its Chief Executive for three years through December 2004. Mr. Pessina was appointed to the
Alliance UniChem Board in 1997 when UniChem merged with Alliance Santé, the Franco-Italian pharmaceutical wholesale group
which he established in Italy in 1977.
Ornella Barra has served as Co-Chief Operating Officer since June 2016. She served as Executive Vice President, President and
Chief Executive of Global Wholesale and International Retail from December 2014 to June 2016. Previously, she served as the
Chief Executive, Wholesale and Brands of Alliance Boots from September 2013 to December 2014 and Chief Executive of the
Pharmaceutical Wholesale Division of Alliance Boots from January 2009 to September 2013, and before that, Wholesale &
Commercial Affairs Director of Alliance Boots. Since January 2015, Ms. Barra has served as a director of AmerisourceBergen.
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Industry Analysis
The retail pharmacy and pharmaceutical wholesale industries across the globe are highly competitive and dynamic and
have experienced consolidation and an evolving competitive landscape in recent years. Prescription drugs will continue to
play significant role in healthcare and constitute a first line of treatment for many medical conditions. Walgreens Boots
Alliance believes the long-term outlook for prescription drug utilization is strong due, in part, to aging populations,
increases in life expectancy, increases in the availability of generic drugs, the continued development of innovative drugs
that improve quality of life and control healthcare costs and increases in the number of persons with insurance coverage
for prescription drugs, including, in the United States, “baby boomers” increasingly becoming eligible for the federally
funded Medicare Part D prescription program. Pharmaceutical wholesalers act as a vital link between drug manufacturers
and pharmacies and healthcare providers in supplying pharmaceuticals to patients. Also, retail pharmacy relies heavily on
private and governmental third-party payers. In addition, in many European countries, the government provides or
subsidizes healthcare to consumers and regulates pharmaceutical prices, patient eligibility and reimbursement levels to
control costs for the government-sponsored healthcare system. Legal and regulatory risk falls into play here. These
industry dynamics and challenges are continuous and have intensified in recent years. Since the completion of the
strategic combination with Alliance Boots in December 2014, the Company has had a continuous focus on operational
efficiencies and cost reduction.
Industry Competition
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90.85
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CVS

Rite Aid

Herbalife LTD

CVS is notably Walgreen’s biggest competitor. They recently merged with
Aetha which helps CVS provide low-cost services to people with Aetha
insurance. Walgreens on the other hand is merging with VillageMD to also
provide lost cost services in a different way. They are allowing people to go to a
nearby VillageMD, that is connected to Walgreens, and provide these services
and then send over prescriptions right next door. This is especially beneficial to
low-income communities that will utilize having doctors’ offices so close and at
a low cost. The pharmaceutical industry is overall stable and is a $296.56 billion
industry. The retail industry however is not as stable with more things switching
online. Walgreens is putting more time and money into upgrading its app and
allowing customer to order online and be able to send prescription medications
to your house. Like stated before with Amazon coming out with the Pill Pack,
Walgreen is a trusted brand that many people already use. They will continue
to have customers despite the increasing number of competitors.

Porter’s Five Forces
• Competitive Rivalry - High
o There are well established competitors like Rite- Aid, CVS, and Walmart. The products that
pharmaceutical companies offer don’t differ much which allows the consumer little to no cost to switch
over to a competitor causing the rivalry to be high.
• Threat of New Entrants - Low
o The threat of new entrants is low because these existing firms are well established brands. One would
need a large amount of capital to establish and compete. They would also have to get licenses that
required by the FDA.
• Bargaining power of Suppliers - Low
o Bargaining power of suppliers is low because suppliers provide Walgreens with raw materials and
equipment. These suppliers are usually in contracts that business both the supplier and Walgreens so it
would be hard to find contracts with well-established companies.
• Bargaining power of Buyers - High
o The bargaining power of buyers is high because there is no switching cost for the consumer to go to a
different store. Most of the stores offer similar products at similar prices.
• Threat of Substitutes - High
o The threat of substitutes is high because as people buy vitamins and continue to live healthier lives, there
will be little need to get prescription medicines. Also, there are homeopathic and herbal medicines that
people might try to replace medications. There are always going to medications that cannot be replaced
as well.
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Financial Analysis
Revenue ($ in Billions)
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Margin

Walgreens Boots Alliance has had a steady revenue increase over the last 10 years. It has a CAGR of 7.65% from 2010 to
2020. This revenue is largely from the retail pharmacy USA segment of this company and 75% of that revenue being from the
pharmaceutical portion. There is projected growth in the next three years as well.
EBIDTA has been also increasing over the last couple of years. There was a slight decrease in 2020 due to the pandemic
causing a lot of stores being shut especially internationally. This is also consistent with the margin ratio as well. There is
predicted increase because of the lower expected operating expenses in the next three years.
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The return on equity measures a corporation's profitability by revealing how much profit a company generates with the
money shareholders have invested, showing the increase from 2014 to 2015 when it merged with Alliance. The negative
means there was a loss in net income, this was due to the closure of stores due to regulations. But since Walgreens is
restricting and not opening as many stores through the Transformational Cost Management Program, the ROE is expected
to increase.
The return on assets has been pretty steady and consistent with the rest of the retail pharmacy industry. An ROA
percentage over 5% is considered good. There is an obvious drop in 2020 due to COVID-19 and the closure of so many
stores in the states and internationally. As more stores are opening back up in the US and internationally, the ROA is
expected increase.
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Gross Margin %

Dividends Per Share
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The gross margin percent has been pretty stable with the pharmaceutical industry. Even though there is slight decrease
over the last couple of years. The pharmaceutical industry has an average gross margin profit of 21.8% and it has been
pretty consistent with that number.
The dividends per share seem to increase at the high rate with a CAGR of 12.11%. Because there is an increase in net
profits out of which dividends are paid and there is more cash flow due to the higher revenues which were showed earlier in
the revenue graph.

Comparable Company Analysis
When comparing Walgreens Boots Alliance among its competitors, it is the second smallest when looking at market cap.
Yet its price to earnings and price to book are slightly higher than CVS, which is its most similar competitor. It also has a
significantly higher price to free cash flow compared to all the other companies. I think even though Walgreens is smaller
than the other companies they are living up to their competitors with their financials.
Ticker

Company

Market Cap

P/E

P/B

P/FCF

CVS

CVS Health

99.61 B

10.10

1.14

9.24

RAD

Rite Aid

1.32 B

-

2.16

20.63

WMT

Walmart

380.67 B

25.25

4.70
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TGT

Target

100.20 B

23.47

6.94

11.61

PETS

PetMed Express Inc

677.46 B
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4.87

6.20

WBA

Walgreens Boots Alliance

44.96 B

10.74

2.24

41.94

WALGREENS BOOTS ALLIANCE | REPORT BY IRIS BOPARAI

Page | 8

Valuation
Dividend Discount Analysis

CASE 1
Three Stage Growth Model
Stage 1 Growth Rate

7.60%
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1

2.52%

$48.54 $52.82 $58.16 $65.02 $74.15 $86.90

$105.96

Stage 2 Growth Rate

3.85%

3.02%

$44.05 $47.47 $51.64 $56.86 $63.55 $72.46

$84.91

Number of Years in
Stage 2

5

3.52%

$40.30 $43.09 $46.42 $50.50 $55.59 $62.13

$70.82
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-1.00%
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$53.16

Cost of Equity Capital
Dividends per share,
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3.52%

5.02%

$32.06 $33.70 $35.58 $37.77 $40.36 $43.47

$47.26

$1.86

Average $56.55
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1.00%

CASE 2
Three Stage Growth Model
Stage 1 Growth Rate
Number of Years in
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3.52%
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$53.35 $59.63 $67.99 $79.67 $97.13 $126.07 $183.39

1.50%

2.52%
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$123.11

5

3.02%
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$92.68

3.52%

$38.68 $41.66 $45.30 $49.85 $55.69 $63.46

$74.32

4.02%

$35.42 $37.84 $40.75 $44.31 $48.75 $54.45

$62.03

4.52%

$32.66 $34.66 $37.03 $39.87 $43.34 $47.68

$53.24

5.02%

$30.29 $31.97 $33.93 $36.24 $39.02 $42.40

$46.63

1

$1.86

Average $58.35

Dividend Discount Analysis Explained
In the first case, I took the predicted growth rates from Yahoo Finance to calculate the average value using the
dividend discount model. With the first year having a high growth rate due to COVID-19 vaccines and testing, I
would expect a higher growth rate. Then in the next five years have a slower growth rate but still increasing,
nonetheless. I wouldn’t expect it increase forever and I predicted a slight decrease in stage 3. This average came
out to be $56.55. This is the price I chose to invest at because I do see the stock growing at a high rate and then
slowing down. I did this again in the second case with more conservative numbers and for it to not increase as
much. This averaged to be $58.35.
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Free Cash Flow Analysis

CASE 1
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$45.55

$46.89

$48.51

$50.51

4.36%

$43.09

$44.04

$45.14

$46.46

$48.04

4.86%

$41.95

$42.75

$43.67

$44.75

$46.03

5.36%

$40.95

$41.63

$42.41

$43.31

$44.37

Three Stage Growth Model
Stage 1 Growth Rate

7.60%

Number of Years in
Stage 1

1

Stage 2 Growth Rate

3.85%

Number of Years in
Stage 2

5

Stage 3 Growth Rate

-1.00%

Growth Path

Linear

Cost of Equity Capital

3.52%

Free Cash Flow, LTM

$746.00

Average

$50.65

k/
terminal
g
-2.00% -1.50% -1.00% -0.50% 0.00% 0.50% 1.00%

CASE 2
Three Stage Growth Model
Stage 1 Growth Rate

2.00%

Number of Years in
Stage 1

1

Stage 2 Growth Rate

1.50%

Number of Years in
Stage 2

5

Stage 3 Growth Rate

-0.50%

Growth Path

Linear

Cost of Equity Capital

3.52%

Free Cash Flow, LTM

$746.00

2.36%

$53.03 $55.44 $58.57 $62.79 $68.80 $78.05 $94.09

2.86%

$50.65 $52.52 $54.87 $57.93 $62.05 $67.91 $76.94

3.36%

$48.72 $50.20 $52.03 $54.32 $57.30 $61.32 $67.05

3.86%

$47.11 $48.32 $49.76 $51.55 $53.79 $56.70 $60.62

4.36%

$45.76 $46.75 $47.93 $49.34 $51.08 $53.27 $56.11

4.86%

$44.61 $45.44 $46.40 $47.55 $48.93 $50.62 $52.76

5.36%

$43.62 $44.31 $45.12 $46.06 $47.18 $48.52 $50.18

Average $54.37

Free Cash Flow Analysis Explained
In the first case, I took the predicted growth rates from Yahoo Finance to calculate the average value using the free cash flow
analysis model. With the first year having a high growth rate due to COVID-19 vaccines and testing, I would expect a higher
growth rate. Then in the next five years have a slower growth rate but still increasing, nonetheless. I wouldn’t expect it increase
forever and I predicted a slight decrease in stage 3. This average came out to be $50.65. I did this again in the second case with
more conservative numbers and for it to not increase as much. This averaged to be $54.37.
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Investment Risks

One of the risks that come with investing in Walgreens is business risks. These can
include the company not being able to generate enough income to maintain
expenses. There is also the risk of competition as Walgreens competes with various
local, regional, national and global retailers, including chain and independent
pharmacies, mail order prescription providers, grocery stores, convenience stores,
mass merchants, online and omni-channel pharmacies and retailers, warehouse
clubs, dollar stores and other discount merchandisers. Some mitigation strategies
can include cutting down on spending to ensure that all debts can be paid off in due
time and continuously looking for ways to stand out from competitors.
There are also technological risks that come with any big company. There is a lot of
patient data and other confidential information stored in the Walgreen’s database. It is
essential that they are equipped to handle and IT or cybersecurity issues that arise.
They also be able to handle any damage that could be done to the technology
including failures, computer viruses, vandalism, theft, etc. Mitigation strategies can
include allocating resources to make sure there are strong firewalls and making sure
employees are trained properly when handling sensitive information.

There are legal and regulatory risks that can be a problem. Walgreens is governed
by national, state and local laws of general applicability in the countries in which it
does business, including laws regulating matters of working conditions, health and
safety and equal employment opportunity. Also, there were government orders to
shut down businesses and there were major stores in big cities in the US and
internationally that were shut down which cost the company to lose a lot of money.
This is a big factor to consider when investing in Walgreens. Some mitigation
strategies that were implemented were the Transformational Cost Management
Program that was put into place after the shutdowns began. Another strategy could
include having a protocol to help navigate pandemics.

There are geopolitical risks that come with any international company. Walgreens
needs to comply with a wide variety of foreign laws and regulations, including retail and
wholesale pharmacy, licensing, tax, foreign trade, intellectual property, privacy and
data protection, immigration, currency, political and other business restrictions and
requirements and local laws and regulations, whose interpretation and enforcement
vary significantly among jurisdictions and can change significantly over time. Mitigation
strategy could be having people in place to keep up with foreign policies to stay on top
of problems that could arise.
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